Lu JF - Search Results

1

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

Claret L, Lu JF, Sun YN, Bruno R. Claret L, et al. Among authors: lu jf. Cancer Chemother Pharmacol. 2010 Nov;66(6):1141-9. doi: 10.1007/s00280-010-1449-z. Epub 2010 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 20872147

2

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Bruno R, Lu JF, Sun YN, Claret L. Bruno R, et al. Among authors: lu jf. J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13. J Clin Pharmacol. 2011. PMID: 20628172 No abstract available.

3

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Melara R, Bruno R, Sun YN. Lu JF, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1151-8. doi: 10.1007/s00280-010-1456-0. Epub 2010 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 20872145

4

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.

Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Bruno R, et al. Among authors: lu jf. Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9. doi: 10.1007/s00280-005-1026-z. Epub 2005 May 3. Cancer Chemother Pharmacol. 2005. PMID: 15868146

5

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Lu JF, et al. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. Cancer Chemother Pharmacol. 2008. PMID: 18205003

6

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN. Lu JF, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1135-44. doi: 10.1007/s00280-011-1787-5. Epub 2012 Jan 1. Cancer Chemother Pharmacol. 2012. PMID: 22210018 Free PMC article. Clinical Trial.

7

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.

Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA. Sun YN, et al. Among authors: lu jf. J Clin Pharmacol. 2005 Apr;45(4):468-76. doi: 10.1177/0091270004272731. J Clin Pharmacol. 2005. PMID: 15778428

8

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL. Lu JF, et al. Clin Pharmacol Ther. 2006 Aug;80(2):136-45. doi: 10.1016/j.clpt.2006.04.007. Clin Pharmacol Ther. 2006. PMID: 16890575 Clinical Trial.

9

Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.

Gosselin NH, Mouksassi MS, Lu JF, Hsu CP. Gosselin NH, et al. Among authors: lu jf. Clin Pharmacol Drug Dev. 2015 Nov;4(6):463-72. doi: 10.1002/cpdd.196. Epub 2015 Jul 23. Clin Pharmacol Drug Dev. 2015. PMID: 27137719

10

Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.

Kay BP, Hsu CP, Lu JF, Sun YN, Bai S, Xin Y, D'Argenio DZ. Kay BP, et al. Among authors: lu jf. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):577-90. doi: 10.1007/s10928-012-9269-x. Epub 2012 Aug 30. J Pharmacokinet Pharmacodyn. 2012. PMID: 22932917 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters